



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The General Manager
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

The General Manager
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai - 400 001

IOLCP/CGC/2019
12 February 2019

Subject: Press Release with respect to Financial Results for the Quarter and nine months ended 31 December 2018

Dear Sir,

Pursuant to Regulations 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release with respect to Financial Results for the Quarter and nine months ended 31 December 2018. The same is also available on the website of the Company i.e. www.iolcp.com.

This is for your information & record please.

Thanking You

Yours faithfully
For IOL Chemicals and Pharmaceuticals Limited



(Krishan Singla)
Vice President and Company Secretary
ICSI membership no: A5584

Press Release

IOL Chemicals and Pharmaceuticals Ltd consistently reports strong performance in Q3' FY19

Ludhiana, 12 February 2019: IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals posted strong performance consistently in the third quarter of financial year 2018-19.

₹ in crore

Particulars	Year on Year (YOY)			Nine Months ended		
	31-12-2018	31-12-2017	% increased	31-12-2018	31-12-2017	% increased
Net Revenue from operations	478.29	262.68	82 %	1263.04	713.44	77 %
EBIDTA	136.36	32.78	316 %	260.68	90.42	188 %
Net Profit	82.24	8.80	835 %	135.05	16.21	733 %

Year on Year (YoY) – December 2018 vis a vis December 2017

- Net Revenue from operations increased by 82% to ₹ 478.29 crore from ₹ 262.68 crore.
- EBIDTA increased to ₹ 136.36 crore from ₹ 32.78 crore showing increase of 316%.
- Net Profit increased by 835 % to ₹ 82.24 crore from ₹ 8.80 crore.

Quarter on Quarter (QoQ) – December 2018 vis a vis September 2018

- Net Revenue from operations increased by 13% to ₹ 478.29 crore from ₹ 422.91 crore.
- EBIDTA increased to ₹ 136.36 crore from ₹ 80.89 crore showing increase of 69%.
- Net Profit increased by 114 % to ₹ 82.24 crore from ₹ 38.40 crore.

Nine months ended 31 December 2018 vis a vis 31 December 2017

- Net Revenue from operations increased by 77% to ₹ 1263.04 crore from ₹ 713.44 crore.
- EBIDTA increased to ₹ 260.68 crore from ₹ 90.42 crore showing increase of 188%.
- Net Profit increased by 733% to ₹ 135.05 crore from ₹ 16.21 crore.



Mr Vijay Garg, Joint Managing Director said "We are delighted with our continued strong operational and financial performance during the quarter. We remain relentlessly focused on improved operational efficiencies, strengthening our customer base and market approach, to continue this growth momentum.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and National Stock Exchange (Code: IOLCP) is one of the leading APIs/ bulk drugs Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 10,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand, Iran etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

